Barclays raised the firm’s price target on Cencora (COR) to $290 from $263 and keeps an Overweight rating on the shares. The company reported a mild operational beat on stronger U.S. Healthcare results, offset by softer International, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR: